Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EQRx Aims To Upend Industry’s Pricing Model, With Me-Too Drugs

Executive Summary

With a $200m series A financing and an illustrious founding team, including Alexis Borisy and Peter Bach, EQRx plans to develop cheap me-too drugs. The start-up could pose a new threat to big pharma.

You may also be interested in...



EQRx Price Disruptor Business Model Faces The Costly Reality Of FDA Drug Development Standards

Start-up firm, with two Chinese-developed drugs for lung cancer in late-stage development, may be particularly vulnerable to the US Food and Drug Administration’s recently stated opposition to the Chinese-only research supporting Eli Lilly’s sintilimab.

Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs

Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.

EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market

EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC141457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel